Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TYK-00540 in Adult Patients With Solid Tumors
NCT06246071Phase 1Recruiting
- Sponsor
- TYK Medicines
- Start
- Jan 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of TYK-00540 in solid tumor, ovarian cancer, triple negative breast cancer (TNBC) and 1 more (4 arms), sponsored by TYK Medicines. Primary endpoints: Dose Limiting Toxicity at 31 days, Recommended Dose for Expansion at 1 year and 2 more. Started Jan 2024; status: recruiting.
02
Drugs
TYK-00540
03
Conditions
solid tumorovarian cancertriple negative breast cancer (TNBC)breast cancer
Beyond the preview
Go deeper on NCT06246071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06246071.